---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027235"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:54:08.140735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric licenses radiation dermatitis product to Aries; eligible for up to $61M in milestones

## Summary
- Akos (Enveric sub) grants Aries exclusive worldwide license for patented radiation dermatitis topical.
- Enveric eligible for up to $61M in aggregate milestone payments plus tiered royalties of 2.5%-10%.
- Market opportunity ~$400M annually; affects ~2M cancer patients per year.
- Aries to lead clinical development and commercialization; Enveric to focus on neuropsychiatric.
- Aries nominates Hari Harikumar as chairman-elect of subsidiary formed for this product.

## SEC filing metadata
- accession: 0001493152-24-027235
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224027235/0001493152-24-027235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224027235/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027235
- JSON: https://secwatch.observer/filing/0001493152-24-027235.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.